CorMedix (CRMD) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed CorMedix (CRMD) over the past year, losing 8.0% versus a loss of 28.7%. Over five years, CRMD leads with a +52.8% price change compared with -1.5% for ZVRA. Zevra Therapeutics is the larger company by market cap ($590.3 million vs $565.9 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs +350.9%).
On valuation, Zevra Therapeutics trades at a lower forward P/E (9.2x vs 20.7x for CorMedix). Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus 52.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | ZVRA |
|---|---|---|
| Share price | $7.26 | $9.94 |
| Market cap | $565.88M | $590.27M |
| 1-day change | -2.68% | -3.21% |
| YTD return | -37.58% | +10.94% |
| 1-year return | -28.68% | -8.01% |
| 5-year return | +52.84% | -1.49% |
| P/E ratio (TTM) | 3.54 | 10.80 |
| Forward P/E | 20.74 | 9.23 |
| EPS (TTM) | $2.05 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $106.47M |
| Revenue growth (YoY) | +617.03% | +350.91% |
| Net income (latest FY) | $163.06M | $83.23M |
| Gross margin | 88.46% | 84.52% |
| Operating margin | 48.17% | -59.12% |
| Net margin | 52.31% | 78.17% |
| 52-week high | $13.02 | $15.04 |
| 52-week low | $6.13 | $8.01 |
| Distance from 52-week high | -44.24% | -33.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.16% | +151.51% |
| Average volume | 1.11M | 1.07M |
| Shares outstanding | 77.94M | 59.38M |
| Employees | 191 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed CRMD by 20.7 percentage points over the past year.
- Zevra Therapeutics trades at a higher earnings multiple (10.8x vs 3.5x trailing P/E).
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus 52.3 cents for CorMedix.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +350.91%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
CRMD vs ZVRA FAQ
Which is bigger, CorMedix or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $590.27M compared with $565.88M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or ZVRA?
ZVRA returned -8.01% over the past 12 months, compared with -28.68% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CRMD or ZVRA?
CRMD has the lower trailing P/E at 3.5, versus 10.8 for ZVRA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are CorMedix and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.